Diabetic Retinopathy - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Diabetic Retinopathy - Pipeline Review, H1 2018’, provides an overview of the Diabetic Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy

- The report reviews pipeline therapeutics for Diabetic Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Diabetic Retinopathy therapeutics and enlists all their major and minor projects

- The report assesses Diabetic Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Diabetic Retinopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abzena Plc

Acucela Inc

Aerie Pharmaceuticals Inc

Antisense Therapeutics Ltd

Applied Therapeutics Inc

Araim Pharmaceuticals Inc

BCN Peptides SA

Boehringer Ingelheim GmbH

Charlesson LLC

Coherus ...

Abzena Plc

Acucela Inc

Aerie Pharmaceuticals Inc

Antisense Therapeutics Ltd

Applied Therapeutics Inc

Araim Pharmaceuticals Inc

BCN Peptides SA

Boehringer Ingelheim GmbH

Charlesson LLC

Coherus BioSciences Inc

Crinetics Pharmaceuticals Inc

Dimerix Bioscience Pty Ltd

Dynamis Therapeutics Inc

EyeGene Inc

EyePoint Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Formycon AG

IMMD Inc

Kodiak Sciences Inc

Kowa Co Ltd

Lupin Ltd

M's Science Corp

Mabion SA

Medy-Tox Inc

Nemus Bioscience Inc

NGM Biopharmaceuticals Inc

Oculis ehf

OcuNexus Therapeutics Inc

Ohr Pharmaceutical Inc

PanOptica Inc

Profarma

Promedior Inc

Protheragen Inc

Regeneron Pharmaceuticals Inc

Rezolute Inc

Ribomic Inc

Strongbridge Biopharma plc

Sylentis SAU

ThromboGenics NV

Unity Biotechnology Inc

VESSL Therapeutics Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Retinopathy – Overview 6

Diabetic Retinopathy – Therapeutics Development 7

Diabetic Retinopathy – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Retinopathy – Overview 6

Diabetic Retinopathy – Therapeutics Development 7

Diabetic Retinopathy – Therapeutics Assessment 18

Diabetic Retinopathy – Companies Involved in Therapeutics Development 29

Diabetic Retinopathy – Drug Profiles 46

Diabetic Retinopathy – Dormant Projects 194

Diabetic Retinopathy – Discontinued Products 198

Diabetic Retinopathy – Product Development Milestones 199

Appendix 209

List of Tables

List of Tables

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Retinopathy – Pipeline by Abzena Plc, H1 2018

Diabetic Retinopathy – Pipeline by Acucela Inc, H1 2018

Diabetic Retinopathy – Pipeline by Aerie Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy – Pipeline by Antisense Therapeutics Ltd, H1 2018

Diabetic Retinopathy – Pipeline by Applied Therapeutics Inc, H1 2018

Diabetic Retinopathy – Pipeline by Araim Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy – Pipeline by BCN Peptides SA, H1 2018

Diabetic Retinopathy – Pipeline by Boehringer Ingelheim GmbH, H1 2018

Diabetic Retinopathy – Pipeline by Charlesson LLC, H1 2018

Diabetic Retinopathy – Pipeline by Coherus BioSciences Inc, H1 2018

Diabetic Retinopathy – Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy – Pipeline by Dimerix Bioscience Pty Ltd, H1 2018

Diabetic Retinopathy – Pipeline by Dynamis Therapeutics Inc, H1 2018

Diabetic Retinopathy – Pipeline by EyeGene Inc, H1 2018

Diabetic Retinopathy – Pipeline by EyePoint Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Diabetic Retinopathy – Pipeline by Formycon AG, H1 2018

Diabetic Retinopathy – Pipeline by IMMD Inc, H1 2018

Diabetic Retinopathy – Pipeline by Kodiak Sciences Inc, H1 2018

Diabetic Retinopathy – Pipeline by Kowa Co Ltd, H1 2018

Diabetic Retinopathy – Pipeline by Lupin Ltd, H1 2018

Diabetic Retinopathy – Pipeline by M's Science Corp, H1 2018

Diabetic Retinopathy – Pipeline by Mabion SA, H1 2018

Diabetic Retinopathy – Pipeline by Medy-Tox Inc, H1 2018

Diabetic Retinopathy – Pipeline by Nemus Bioscience Inc, H1 2018

Diabetic Retinopathy – Pipeline by NGM Biopharmaceuticals Inc, H1 2018

Diabetic Retinopathy – Pipeline by Oculis ehf, H1 2018

Diabetic Retinopathy – Pipeline by OcuNexus Therapeutics Inc, H1 2018

Diabetic Retinopathy – Pipeline by Ohr Pharmaceutical Inc, H1 2018

Diabetic Retinopathy – Pipeline by PanOptica Inc, H1 2018

Diabetic Retinopathy – Pipeline by Profarma, H1 2018

Diabetic Retinopathy – Pipeline by Promedior Inc, H1 2018

Diabetic Retinopathy – Pipeline by Protheragen Inc, H1 2018

Diabetic Retinopathy – Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy – Pipeline by Rezolute Inc, H1 2018

Diabetic Retinopathy – Pipeline by Ribomic Inc, H1 2018

Diabetic Retinopathy – Pipeline by Strongbridge Biopharma plc, H1 2018

Diabetic Retinopathy – Pipeline by Sylentis SAU, H1 2018

Diabetic Retinopathy – Pipeline by ThromboGenics NV, H1 2018

Diabetic Retinopathy – Pipeline by Unity Biotechnology Inc, H1 2018

Diabetic Retinopathy – Pipeline by VESSL Therapeutics Ltd, H1 2018

Diabetic Retinopathy – Dormant Projects, H1 2018

Diabetic Retinopathy – Dormant Projects, H1 2018 (Contd..1), H1 2018

Diabetic Retinopathy – Dormant Projects, H1 2018 (Contd..2), H1 2018

Diabetic Retinopathy – Dormant Projects, H1 2018 (Contd..3), H1 2018

Diabetic Retinopathy – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports